Performance of the systemic lupus erythematosus risk probability index (SLERPI) in the Egyptian college of rheumatology (ECR) study cohort

• Published in: Clinical rheumatology
• Main Authors: Hammam, Nevin, Elsaman, Ahmed, Abualfadl, Esam, Senara, Soha, Gamal, Nada M., Abd-Elsamea, Mona H., Moshrif, Abdelhfeez, Hammam, Osman, Gheita, Tamer A., Tharwat, Samar
• Format: Journal Article
• Language: English
• Published: 04-11-2024
• ISSN: 0770-3198; 1434-9949; 1434-9949
• DOI: 10.1007/s10067-024-07210-0

Abstract Objectives This study aimed to evaluate the performance of systemic lupus erythematosus Risk Probability Index (SLERPI) in Egyptian patients with SLE using a national rheumatology database. Methods The Egyptian College of Rheumatology (ECR) database comprised of 1,162 patients with SLE and 4,327 with miscellaneous rheumatological diseases who were recruited from the Rheumatology Departments across the country. The diagnosis of SLE was established by expert rheumatologists. Variables of the SLERPI were extracted and recorded as present or absent for each patient. The absolute value for the SLERPI score was calculated for each patient, and the diagnosis of SLE was accounted for if the score was greater than 7 points. Results Of 1,162 SLE patients evaluated, 1,031 (88.7%) patients were diagnosed with SLE according to the SLERPI, with an average score of 13.1 (3.8). Differences in the 14 SLERPI variables were significant between the SLE-SLERPI groups, except for the presence of leukopenia and positive ANA. As a score reduction item, the SLE-SLERPI > 7 group had lower interstitial lung diseases. Patients diagnosed with SLE according to SLERPI had significantly higher disease activity ( p < 0.001), and this group more commonly received corticosteroids and mycophenolate mofetil. Compared to other miscellaneous rheumatological groups, all 14 SLERPI items are indeed more common in the SLE group. In terms of the overall performance of SLERPI in the diagnosis of SLE, the accuracy of SLERPI was 91.9% (95% CI 90.9%—92.9%), with a specificity of 96.95% and sensitivity of 86.9%. SLERPI showed that accuracy went up to 93.3% (95%CI 92.4%-94.2%), with a specificity of 94.9% and a sensitivity of 91.6% when patients with connective tissue diseases were taken out of the study. Conclusion Using a large cohort of SLE, the SLERPI revealed excellent diagnostic efficacy and specificity. The use of SLERPI in clinical practice may contribute to improved patient diagnosis and prognosis. Key Points • SLERPI's performance has high diagnostic efficiency in Egyptian SLE patients. • SLERPI score can efficiently distinguish patients with SLE from other CTDs. • Within the SLERPI score, interstitial lung disease is the lowest predictor of SLE.